Articles related to CLINICAL STUDY

Researchers studied the effects of four repeated low doses of LSD, administered under lab conditions every three to four days, using approximately 1/8th the dose typically used to “trip” on LSD.

Gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) AML but seldom reduces FLT3mut burden or induces sustained efficacy. This phase Ib open-label, dose-escalation/dose-expansion study enrolled 61 patients (63% having received prior FLT3 therapy) to receive 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The combination of venetoclax and gilteritinib was associated with high mCRc and FLT3 molecular response rates regardless of prior FLT3 inhibitor exposure, but did require dose interruptions for myelosuppression.

A detailed summarization of the clinical presentation of 197 individuals with PCR-confirmed diagnosis of monkeypox in the UK. The summary documents a highly variable prodrome in terms of prodromal symptoms and timing to eruption of visible lesions. Systemic illness was seen in 86% of patients. After mucocutaneous lesions, seen in 100% of patients, fever was the next most common manifestation, seen in 62% of patients.

“Eszopiclone and lemborexant work for insomnia despite adverse events, while prescription drugs such as benzodiazepines, daridorexant, suvorexant, and trazodone can be effective but are associated with poor tolerability, according to this systematic review and meta-analysis.”

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

In this study of neoadjuvant chemotherapy with ruxolitinib, approximately 130 patients were randomized to receive dose-dense neoadjuvant chemotherapy with or without ruxolitinib, followed by interval debulking and finally three more cycles of dose-dense neoadjuvant chemotherapy with or without ruxolitinib. The ruxolitinib group experienced a 3-month difference in progression-free survival.